EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function

Gérard Greig, Nader N Youssef, Federico Bolognani

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2423 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Gérard Greig und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ironwood Pharmaceuticals, Basel, Switzerland. Hauptthemen laut MEDLINE: Renal Insufficiency, Area Under Curve. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ironwood Pharmaceuticals, Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal impairment is a common complication in patients with short bowel syndrome with intestinal failure (SBS‐IF). Glucagon‐like peptide‐2 analogs, such as apraglutide, have been developed as a treatment option for SBS‐IF. This study assessed the potential for apraglutide overexposure in individuals with severely impaired renal function versus healthy volunteers with normal renal function. In this phase 1, open‐label, multicenter, nonrandomized, parallel‐group study, a single dose of apraglutide 5 mg was administered subcutaneously to individuals with severely impaired renal function (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal InsufficiencyArea Under CurveHumansMaleFemaleMiddle AgedAdultAgedGlucagon-Like Peptide 2Short Bowel Syndrome

Stichwörter der Autor:innen

apraglutidedrug exposurepharmacokineticsrenal impairmentshort bowel syndrome

Substanzen

Glucagon-Like Peptide 2

Autor:innen und Institutionen

  • Ironwood Pharmaceuticals, Basel, Switzerland.

Förderung

  • Ironwood Pharmaceuticals, Incorporated

Zitieren

APA

Greig, G., Youssef, N. N., & Bolognani, F. (2024). Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2423

Vancouver

Greig G, Youssef NN, Bolognani F. Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2423

BibTeX
@article{Greig2024,
  author = {Greig, Gérard and Youssef, Nader N and Bolognani, Federico},
  title = {Pharmacokinetics and Tolerability of a Single Dose of Apraglutide, a Novel, Long‐Acting, Synthetic glucagon‐like peptide‐2 Analog With a Unique Pharmacologic Profile, in Individuals With Impaired Renal Function},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2423}
}
Kostenlos starten →